SCHEMBL585488

SCHEMBL585488

C=CCC(Oc1ccccc1)C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARG P37231 19/20 0.53
PPARA Q07869 17/20 0.53
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3085599 0.86 CYP2C19 (0.45) PPARGPPARACYP2C19
SCHEMBL11667295 0.86 CYP2C19 (0.45) PPARGPPARACYP2C19
SCHEMBL3312435 0.86 CYP2C19 (0.45) PPARGPPARACYP2C19
SCHEMBL1326852 0.85 CYP2C19 (0.44) PPARGPPARACYP2C19
SCHEMBL28442511 0.84 PPARG (0.54) PPARGPPARA
SCHEMBL7329105 0.83 TSHR (0.44) PPARGPPARACYP2C19
SCHEMBL3312014 0.83 CYP2C19 (0.42) PPARGPPARACYP2C19
SCHEMBL9062048 0.83 PPARG (0.61) PPARGPPARA
SCHEMBL9062031 0.82 PPARG (0.49) PPARGPPARA
SCHEMBL4874812 0.81 PPARG (0.62) PPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 609 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250283018-A1 TOILET RIM BLOCKS WITH SCENT CHANGE SYMRISE AG (DE) 2025-09-11 US claimed
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION SYMRISE AG (DE) 2024-04-18 US claimed
EP-4291154-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION Symrise AG (DE) 2023-12-20 EP claimed
EP-3416729-B1 PRO-FRAGRANCE COMPOSITION AQDOT LTD (GB) 2023-09-20 EP claimed
EP-3423028-B1 METHOD FOR THE PRODUCTION OF ENCAPSULATED FRAGRANCE WITH IMPROVED STABILITY AGAINST DETERGENTS SYMRISE AG (DE) 2020-04-08 EP claimed
WO-2014187576-A1 DEODORIZING ACTIVE INGREDIENT COMBINATION HENKEL AG & CO. KGAA (DE) 2014-11-27 WO claimed
EP-2020225-B1 Fragrance composition KAO CORP (JP) 2014-10-08 EP claimed
WO-2011101181-A1 PERFUME COMPOSITIONS HENKEL AG & CO. KGAA (DE) 2011-08-25 WO claimed
EP-1716159-B1 BICYCLIC SILOXANE COMPOSITIONS FOR THE RELEASE OF ACTIVE INGREDIENTS MOMENTIVE PERFORMANCE MAT INC (US) 2011-07-13 EP claimed
EP-2211829-B1 IMPROVEMENT OF THE FRAGRANCE EFFECT OF PERFUME ESTERS HENKEL AG & CO KGAA (DE) 2011-04-27 EP claimed
US-20100210496-A1 Fragrance Effect of Perfume Esters BESSLER CORNELIUS 2010-08-19 US claimed
EP-2211829-A1 IMPROVEMENT OF THE FRAGRANCE EFFECT OF PERFUME ESTERS Henkel AG & Co. KGaA (DE) 2010-08-04 EP claimed
WO-2009059858-A1 IMPROVEMENT OF THE FRAGRANCE EFFECT OF PERFUME ESTERS HENKEL AG & CO. KGAA (DE) 2009-05-14 WO claimed
EP-1948773-A1 FRAGRANT CONSUMER PRODUCTS COMPRISING OXIDIZING AGENTS Henkel AG & Co. KGaA (DE) 2008-07-30 EP claimed
EP-1290132-B1 FABRIC CARE COMPOSITIONS AND SYSTEMS FOR DELIVERING CLEAN, FRESH SCENT IN A LIPOPHILIC FLUID TREATMENT PROCESS PROCTER & GAMBLE (US) 2008-04-30 EP claimed
EP-1697386-B1 ACTIVE INGREDIENT-RELEASING CYCLIC SILOXANES GEN ELECTRIC (US) 2007-10-10 EP claimed
WO-2007054177-A1 FRAGRANT CONSUMER PRODUCTS COMPRISING OXIDIZING AGENTS HENKEL AG & CO. KGAA (DE) 2007-05-18 WO claimed
EP-0520226-B2 Halogen scavenger composition ST CHEMICAL CO LTD (JP) 2000-10-11 EP claimed
EP-0058605-B1 MICROEMULSION OF WATER IN A LIQUID COMBUSTIBLE SOCIETE NATIONALE ELF AQUITAINE (FR) 1986-08-27 EP claimed
EP-0058605-A2 Microemulsion of water in a liquid combustible SOCIETE NATIONALE ELF AQUITAINE (FR) 1982-08-25 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240122834-A1 MEDICAMENT FOR PREVENTION AND TREATMENT OF HYPERPIGMENTATION MC1R, OR51E2, TYR PPARG 235/4885PPARA 217/4885CYP2C19 4786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.